Cargando…

Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics

BACKGROUND: A definitive diagnosis of malignant peripheral nerve sheath tumor (MPNST) is challenging, especially in cases without neurofibromatosis 1 (NF1), because MPNST lacks specific markers on immunohistochemistry (IHC). METHODS: We performed IHC for histone 3 trimethylated on lysine 27 (H3K27me...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugita, Shintaro, Aoyama, Tomoyuki, Emori, Makoto, Kido, Tomomi, Takenami, Tomoko, Sakuraba, Kodai, Terai, Kotomi, Sugawara, Taro, Tsujiwaki, Mitsuhiro, Hasegawa, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404283/
https://www.ncbi.nlm.nih.gov/pubmed/34461930
http://dx.doi.org/10.1186/s13000-021-01140-0
_version_ 1783746138835255296
author Sugita, Shintaro
Aoyama, Tomoyuki
Emori, Makoto
Kido, Tomomi
Takenami, Tomoko
Sakuraba, Kodai
Terai, Kotomi
Sugawara, Taro
Tsujiwaki, Mitsuhiro
Hasegawa, Tadashi
author_facet Sugita, Shintaro
Aoyama, Tomoyuki
Emori, Makoto
Kido, Tomomi
Takenami, Tomoko
Sakuraba, Kodai
Terai, Kotomi
Sugawara, Taro
Tsujiwaki, Mitsuhiro
Hasegawa, Tadashi
author_sort Sugita, Shintaro
collection PubMed
description BACKGROUND: A definitive diagnosis of malignant peripheral nerve sheath tumor (MPNST) is challenging, especially in cases without neurofibromatosis 1 (NF1), because MPNST lacks specific markers on immunohistochemistry (IHC). METHODS: We performed IHC for histone 3 trimethylated on lysine 27 (H3K27me3) and evaluated the percentage of cells with H3K27me3 loss using measured values at 10% intervals, categorized as complete loss (100% of tumor cells lost staining), partial loss (10% to 90% of tumor cells lost staining), and intact (no tumor cells lost staining). We conducted fluorescence in situ hybridization (FISH) for NF1 and p16 deletions comparing 55 MPNSTs and 35 non-MPNSTs, consisting of 9 synovial sarcomas (SSs), 8 leiomyosarcomas (LMSs), 10 myxofibrosarcomas (MFSs), and 8 undifferentiated pleomorphic sarcomas (UPSs). We assessed the percentage of cells with homozygous and heterozygous deletions and defined “deletion” if the percentage of either the NF1 or p16 deletion signals was greater than 50% of tumor cells. RESULTS: Among the 55 MPNSTs, 23 (42%) showed complete H3K27me3 loss and 32 (58%) exhibited partial loss or intact. One each of the 9 SSs (11%), 8 LMSs (12%), and 8 UPSs (12%) showed complete H3K27me3 loss and many non-MPNSTs exhibited intact or partial H3K27me3 loss. Among the 55 MPNSTs, 33 (60%) and 44 (80%) showed NF1 or p16 deletion, respectively. Co-deletion of NF1 and p16 was observed in 29 (53%) MPNSTs. Among the 23 MPNTSs showing H3K27me3 complete loss, 18 (78%) and 20 (87%) exhibited NF1 or p16 deletion, respectively. Among the 32 MPNSTs with H3K27me3 partial loss or intact, 15 (47%) and 24 (75%) exhibited NF1 or p16 deletion, respectively. The frequency of NF1 and/or p16 deletion tended to be lower in non-MPNSTs than in MPNSTs. Approximately 90% of MPNSTs included cases with H3K27me3 complete loss and cases showing H3K27me3 partial loss or intact with NF1 and/or p16 deletion. Approximately 50% of MPNSTs showed co-deletion of NF1 and p16 regardless of H3K27me3 loss. CONCLUSIONS: FISH for NF1 and p16 deletions, frequently observed in high-grade MPNSTs, might be a useful ancillary diagnostic tool for differentiating MPNST from other mimicking spindle cell and pleomorphic sarcomas.
format Online
Article
Text
id pubmed-8404283
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84042832021-08-30 Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics Sugita, Shintaro Aoyama, Tomoyuki Emori, Makoto Kido, Tomomi Takenami, Tomoko Sakuraba, Kodai Terai, Kotomi Sugawara, Taro Tsujiwaki, Mitsuhiro Hasegawa, Tadashi Diagn Pathol Research BACKGROUND: A definitive diagnosis of malignant peripheral nerve sheath tumor (MPNST) is challenging, especially in cases without neurofibromatosis 1 (NF1), because MPNST lacks specific markers on immunohistochemistry (IHC). METHODS: We performed IHC for histone 3 trimethylated on lysine 27 (H3K27me3) and evaluated the percentage of cells with H3K27me3 loss using measured values at 10% intervals, categorized as complete loss (100% of tumor cells lost staining), partial loss (10% to 90% of tumor cells lost staining), and intact (no tumor cells lost staining). We conducted fluorescence in situ hybridization (FISH) for NF1 and p16 deletions comparing 55 MPNSTs and 35 non-MPNSTs, consisting of 9 synovial sarcomas (SSs), 8 leiomyosarcomas (LMSs), 10 myxofibrosarcomas (MFSs), and 8 undifferentiated pleomorphic sarcomas (UPSs). We assessed the percentage of cells with homozygous and heterozygous deletions and defined “deletion” if the percentage of either the NF1 or p16 deletion signals was greater than 50% of tumor cells. RESULTS: Among the 55 MPNSTs, 23 (42%) showed complete H3K27me3 loss and 32 (58%) exhibited partial loss or intact. One each of the 9 SSs (11%), 8 LMSs (12%), and 8 UPSs (12%) showed complete H3K27me3 loss and many non-MPNSTs exhibited intact or partial H3K27me3 loss. Among the 55 MPNSTs, 33 (60%) and 44 (80%) showed NF1 or p16 deletion, respectively. Co-deletion of NF1 and p16 was observed in 29 (53%) MPNSTs. Among the 23 MPNTSs showing H3K27me3 complete loss, 18 (78%) and 20 (87%) exhibited NF1 or p16 deletion, respectively. Among the 32 MPNSTs with H3K27me3 partial loss or intact, 15 (47%) and 24 (75%) exhibited NF1 or p16 deletion, respectively. The frequency of NF1 and/or p16 deletion tended to be lower in non-MPNSTs than in MPNSTs. Approximately 90% of MPNSTs included cases with H3K27me3 complete loss and cases showing H3K27me3 partial loss or intact with NF1 and/or p16 deletion. Approximately 50% of MPNSTs showed co-deletion of NF1 and p16 regardless of H3K27me3 loss. CONCLUSIONS: FISH for NF1 and p16 deletions, frequently observed in high-grade MPNSTs, might be a useful ancillary diagnostic tool for differentiating MPNST from other mimicking spindle cell and pleomorphic sarcomas. BioMed Central 2021-08-30 /pmc/articles/PMC8404283/ /pubmed/34461930 http://dx.doi.org/10.1186/s13000-021-01140-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sugita, Shintaro
Aoyama, Tomoyuki
Emori, Makoto
Kido, Tomomi
Takenami, Tomoko
Sakuraba, Kodai
Terai, Kotomi
Sugawara, Taro
Tsujiwaki, Mitsuhiro
Hasegawa, Tadashi
Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title_full Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title_fullStr Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title_full_unstemmed Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title_short Assessment of H3K27me3 immunohistochemistry and combination of NF1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
title_sort assessment of h3k27me3 immunohistochemistry and combination of nf1 and p16 deletions by fluorescence in situ hybridization in the differential diagnosis of malignant peripheral nerve sheath tumor and its histological mimics
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404283/
https://www.ncbi.nlm.nih.gov/pubmed/34461930
http://dx.doi.org/10.1186/s13000-021-01140-0
work_keys_str_mv AT sugitashintaro assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT aoyamatomoyuki assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT emorimakoto assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT kidotomomi assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT takenamitomoko assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT sakurabakodai assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT teraikotomi assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT sugawarataro assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT tsujiwakimitsuhiro assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics
AT hasegawatadashi assessmentofh3k27me3immunohistochemistryandcombinationofnf1andp16deletionsbyfluorescenceinsituhybridizationinthedifferentialdiagnosisofmalignantperipheralnervesheathtumoranditshistologicalmimics